pyrazines has been researched along with Leukemia, Myelomonocytic, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleskog, A; Ekholm, C; Eriksson, A; Fhölenhag, K; Hassan, SB; Höglund, M; Jensen, AJ; Larsson, R; Lindhagen, E; Löthgren, A; Parrow, V; Scobie, M | 1 |
| Boe, A; Buffolino, S; Cedrone, M; Diverio, D; Foà, R; Lo-Coco, F; Mariani, G; Peschle, C; Riccioni, R; Riti, V; Senese, M; Testa, U | 1 |
2 other study(ies) available for pyrazines and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Epithelial Cells; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Acute; Male; Mice; Middle Aged; Molecular Structure; Pyrazines; Xenograft Model Antitumor Assays; Young Adult | 2010 |
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
Topics: Aldehyde Dehydrogenase; Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Cells, Cultured; Fas-Associated Death Domain Protein; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Stem Cells; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2007 |